CoChat

Oral Glibenclamide Suppresses Glucagon Secretion during Insulin-Induced Hypoglycemia in Patients with Type 2 Diabetes1

Landstedt-Hallin, Lena, Adamson, Ulf, Lins, Per-Eric · 1999 · The Journal of Clinical Endocrinology & Metabolism
Cited by 65

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

Intensifying pharmacological therapy in patients with type 2 diabetes increases the risk of hypoglycemia and often requires the simultaneous use of more than one agent. Combining insulin and sulfonylurea is an effective and frequently used therapy in such patients. However, sulfonylurea derivatives have been shown to affect the release of glucagon, indicating a possible effect of such therapy on hormonal counterregulation to hypoglycemia. Thirteen patients receiving combined therapy were studied on two occasions: 1) after a wash-out period of glibenclamide (−GLIB), and 2) after resuming combined treatment for 6 months (+GLIB). We performed nonstepwise, hyperinsulinemic hypoglycemic clamps using a constant iv insulin infusion and clamping blood glucose at 2.7 mmol/L (48 mg/dL) for 60 min. C Peptide levels were significantly higher during +GLIB, but no significant differences were seen in peripheral plasma insulin levels (+GLIB mean ± sd, 70 ± 17 mU/L vs. −GLIB, 75 ± 14; P = 0.26). Epinephrine responses were similar in the two tests, but when glibenclamide was present the glucagon response was smaller, both the peak value (P = 0.016) and the incremental area under the curve (P = 0.011) as well as the total area under the curve (P = 0.016). These results suggest that intraislet insulin secretion is of importance for the α-cell responsiveness to hypoglycemia in these patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jcem.84.9.6002

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Research works printed but not linked: 31

  1. 1993, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group., N Engl J Med, 329, 977, 10.1056/NEJM199309303291401 · DOI · Paper page
  2. Andersson, 1995, Long-term glycemic control relates to mortality in type II diabetes., Diabetes Care, 18, 1534, 10.2337/diacare.18.12.1534 · DOI · Paper page
  3. Gaster, 1998, The effects of improved glycemic control on complications in type 2 diabetes., Arch Intern Med, 158, 134, 10.1001/archinte.158.2.134 · DOI · Paper page
  4. 1998, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group., Lancet, 352, 837, 10.1016/S0140-6736(98)07019-6 · DOI · Paper page
  5. De Feo, 1991, Evidence against important catecholamine compensation for absent glucagon counterregulation, Am J Physiol., 260, E203
  6. Pugh, 1992, Is combination sulfonylurea and insulin therapy useful in NIDDM patients? A metaanalysis., Diabetes Care, 15, 953, 10.2337/diacare.15.8.953 · DOI · Paper page
  7. Shank, 1995, Bedtime insulin/daytime glipizide. Effective therapy for sulfonylurea failures in NIDDM., Diabetes, 44, 165, 10.2337/diab.44.2.165 · DOI · Paper page
  8. 1983, The Berson memorial lecture. Insulin-glucagon relationships in the defense against hypoglycemia., Diabetes, 32, 575, 10.2337/diab.32.6.575 · DOI · Paper page
  9. Hjemdahl, 1979, Determination of plasma catecholamines by high performance liquid chromatography with electrochemical detection: comparison with a radioenzymatic method., Life Sci, 25, 131, 10.1016/0024-3205(79)90384-9 · DOI · Paper page
  10. Taborsky, 1998, Autonomic mediation of glucagon secretion during hypoglycemia: implications for impaired α-cell responses in type 1 diabetes., Diabetes, 47, 995, 10.2337/diabetes.47.7.995 · DOI · Paper page
  11. Samols, 1983, 2, 133
  12. Bonner-Weir, 1982, New perspectives on the microvasculature of the islets of Langerhans in the rat., Diabetes, 31, 883, 10.2337/diab.31.10.883 · DOI · Paper page
  13. Asplin, 1981, In vivo inhibition of glucagon secretion by paracrine beta cell activity in man., J Clin Invest, 68, 314, 10.1172/JCI110251 · DOI · Paper page
  14. Mellman, 1992, Effect of physiological hyperinsulinemia on counterregulatory hormone responses during hypoglycemia in humans., J Clin Endocrinol Metab, 75, 1293
  15. Efendic, 1979, Effect of glucose/sulfonylurea interaction on release of insulin, glucagon, and somatostatin from isolated perfused rat pancreas., Proc Natl Acad Sci USA, 76, 5901, 10.1073/pnas.76.11.5901 · DOI · Paper page
  16. Samols, 1969, Suppression of pancreatic glucagon release by the hypoglycaemic sulphonylureas., Lancet, 1, 174, 10.1016/S0140-6736(69)91189-1 · DOI
  17. Buchanan, 1969, Pancreatic glucagon release and sulphonylureas., Lancet, 1, 420, 10.1016/S0140-6736(69)91394-4 · doi:10.1016/s0140-6736(69)91394-4
  18. Kajinuma, 1974, Effects of hypoglycemic sulfonamides on glucagon and insulin secretion in ducks and dogs., Diabetes, 23, 412, 10.2337/diab.23.5.412 · DOI
  19. Pek, 1972, Failure of sulfonylureas to suppress plasma glucagon in man., Diabetes, 21, 216, 10.2337/diab.21.4.216 · DOI
  20. Ohneda, 1975, Glucagon response to arginine after treatment of diabetes mellitus., Diabetes, 24, 811, 10.2337/diab.24.9.811 · DOI
  21. Tsalikian, 1977, The effect of chronic oral antidiabetic therapy on insulin and glucagon responses to a meal., Diabetes, 26, 314, 10.2337/diab.26.4.314 · DOI
  22. Pfeifer, 1983, Suppression of glucagon secretion during a tolbutamide infusion in normal, and noninsulin-dependent diabetic subjects., J Clin Endocrinol Metab, 56, 586, 10.1210/jcem-56-3-586 · DOI · Paper page
  23. Lewis, 1994, A new method for comparing portal and peripheral venous insulin delivery in humans: tolbutamide vs. insulin infusion., J Clin Endocrinol Metab, 79, 66
  24. Peacey, 1997, The use of tolbutamide-induced hypoglycemia to examine the intraislet role of insulin in mediating glucagon release in normal humans., J Clin Endocrinol Metab, 82, 1458
  25. Bohannon, 1982, Stimulatory effects of tolbutamide infusion on plasma glucagon in insulin-dependent diabetic subjects., J Clin Endocrinol Metab, 54, 459, 10.1210/jcem-54-2-459 · DOI · Paper page
  26. Polonsky, 1984, Glucose counterregulation in patients after pancreatectomy. Comparison with other clinical forms of diabetes., Diabetes, 33, 1112, 10.2337/diab.33.11.1112 · DOI · Paper page
  27. Madsbad, 1982, Hormonal, metabolic and cardiovascular responses to hypoglycaemia in type 1 (insulin-dependent) diabetes with and without residual B cell function., Diabetologia, 23, 499, 10.1007/BF00254298 · DOI
  28. Lev-Ran, 1993, C-Peptide in NIDDM. Follow-up for 4–6 yr., Diabetes Care, 16, 76, 10.2337/diacare.16.1.76 · doi:10.2337/diacare.16.1.76
  29. Jennings, 1989, Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents., Diabetes Care, 12, 203, 10.2337/diacare.12.3.203 · DOI · Paper page
  30. Asplund, 1983, Glibenclamide-associated hypoglycaemia: a report on 57 cases., Diabetologia, 24, 412, 10.1007/BF00257338 · DOI · Paper page
  31. Stepka, 1993, Hypoglycemia: a major problem in the management of diabetes in the elderly., Aging, 5, 117

Cited by

Metadata

Authors
Landstedt-Hallin, L., Adamson, U., & Lins, P.-E.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
1999-09-01
Volume
84
Issue
9
Pages
3140-3145
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2134576974
Cited by
65
References
22
FWCI
1.49
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.